GB202217820D0 - Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof - Google Patents
Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereofInfo
- Publication number
- GB202217820D0 GB202217820D0 GBGB2217820.6A GB202217820A GB202217820D0 GB 202217820 D0 GB202217820 D0 GB 202217820D0 GB 202217820 A GB202217820 A GB 202217820A GB 202217820 D0 GB202217820 D0 GB 202217820D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pregabalin
- pharmaceutically acceptable
- pharmaceutical compositions
- acceptable salts
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title 1
- 229960001233 pregabalin Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2217820.6A GB202217820D0 (en) | 2022-11-28 | 2022-11-28 | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2217820.6A GB202217820D0 (en) | 2022-11-28 | 2022-11-28 | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202217820D0 true GB202217820D0 (en) | 2023-01-11 |
Family
ID=84889643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2217820.6A Pending GB202217820D0 (en) | 2022-11-28 | 2022-11-28 | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202217820D0 (en) |
-
2022
- 2022-11-28 GB GBGB2217820.6A patent/GB202217820D0/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL197574A0 (en) | Pharmaceutical compositions | |
| WO2018165404A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| KR20220035361A (en) | GLP-1 Pharmaceutical composition comprising sustained release-microsphere comprising GLP-1 Analogue or pharmaceutically acceptable salt thereof | |
| WO2009066315A3 (en) | Sustained release compositions of trimetazidine and process for preparation thereof | |
| WO2008020040A3 (en) | 2,5-dihydroxybenzene compounds for the treatment of fibrosis | |
| MX2010007083A (en) | Anti - retroviral combination. | |
| PL2205279T3 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| MY162494A (en) | Solid pharmaceutical compositions containing an integrase inhibitor | |
| WO2019203771A3 (en) | Solid oral pharmaceutical compositions comprising sitagliptin | |
| JO3587B1 (en) | Oral dosage forms of bendamustine | |
| HRP20221344T1 (en) | New acetaminophen compound composition without side effect to liver | |
| WO2012020301A3 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| GB202217820D0 (en) | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof | |
| MX2021010596A (en) | Oseltamivir-containing pharmaceutical composition. | |
| WO2020009675A3 (en) | Solid oral pharmaceutical compositions of linagliptin | |
| JO3239B1 (en) | Galenical Formulations of Organic Compounds | |
| MX2021011795A (en) | Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile. | |
| EP4110301A4 (en) | Pharmaceutical composition for oral administration | |
| WO2020032883A3 (en) | Synergistic effects of a novel ketoprofen formulation including a gastro protective agent | |
| WO2007035816A3 (en) | Paroxetine compositions | |
| GB202212116D0 (en) | Pharmaceutically acceptable salts and Compositions thereof | |
| WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation | |
| WO2019209217A3 (en) | Modified release formulations of flurbiprofen | |
| WO2019203759A3 (en) | Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation. | |
| WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate |